Bipartisan Push To Overrule CMS On Alzheimer's Drugs Grows

Members of both parties on key health care committees are increasingly pushing back on CMS’ decision to limit coverage of the anti-amyloid class of emerging drugs intended to treat early stages of Alzheimer’s disease, calling for a reversal of the restriction and putting forth legislation that would require the agency to consider each FDA-approved drug individually, rather than as part of a class. A CMS spokesperson told Inside Health Policy that the final national coverage determination (NCD) for anti-amyloids...